Sozinibercept Shows Promise in Wet AMD Treatment as Opthea's Pivotal Trials Progress
Opthea's sozinibercept (OPT-302) demonstrates potential to enhance visual outcomes in wet age-related macular degeneration patients without competing with standard anti-VEGF-A therapies.
© Copyright 2025. All Rights Reserved by MedPath